Patient Square Capital LP Makes New $4.30 Million Investment in Amylyx Pharmaceuticals, Inc. $AMLX

Patient Square Capital LP bought a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 316,312 shares of the company’s stock, valued at approximately $4,299,000. Amylyx Pharmaceuticals makes up about 1.1% of Patient Square Capital LP’s holdings, making the stock its 18th biggest holding.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. California State Teachers Retirement System purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth about $28,000. Ameritas Investment Partners Inc. bought a new stake in Amylyx Pharmaceuticals during the 2nd quarter worth approximately $45,000. BNP Paribas Financial Markets lifted its stake in Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after purchasing an additional 5,904 shares in the last quarter. Legal & General Group Plc bought a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at $47,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at $103,000. 95.84% of the stock is currently owned by institutional investors.

Amylyx Pharmaceuticals Trading Down 0.1%

AMLX opened at $14.01 on Monday. The stock has a market capitalization of $1.54 billion, a P/E ratio of -7.78 and a beta of -0.31. The stock has a 50-day moving average price of $13.47 and a 200-day moving average price of $12.83. Amylyx Pharmaceuticals, Inc. has a 12-month low of $2.60 and a 12-month high of $17.49.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AMLX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Monday, December 29th. Lifesci Capital upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 27th. Bank of America raised their price target on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a report on Friday. Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, HC Wainwright upped their price objective on shares of Amylyx Pharmaceuticals from $20.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $18.63.

Insiders Place Their Bets

In other news, insider Camille L. Bedrosian sold 6,580 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $14.35, for a total value of $94,423.00. Following the completion of the sale, the insider directly owned 175,756 shares in the company, valued at approximately $2,522,098.60. The trade was a 3.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Karen Firestone acquired 8,100 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The stock was acquired at an average cost of $12.45 per share, with a total value of $100,845.00. Following the purchase, the director directly owned 63,100 shares in the company, valued at $785,595. This represents a 14.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold 157,783 shares of company stock valued at $2,122,808 over the last 90 days. Company insiders own 12.30% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.